Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery

Intensive anticancer drug discovery efforts have been made to develop small molecule inhibitors of the p53-MDM2 and p53-MDMX interactions. We present here the structures of the most potent inhibitors bound to MDM2 and MDMX that are based on the new imidazo-indole scaffold. In addition, the structure of the recently reported spiro-oxindole inhibitor bound to MDM2 is described. The structures indicate how the substituents of a small molecule that bind to the three subpockets of the MDM2/X-p53 interaction should be optimized for effective binding to MDM2 and/or MDMX. While the spiro-oxindole inhibitor triggers significant ligand-induced changes in MDM2, the imidazo-indoles share similar binding modes for MDMX and MDM2, but cause only minimal induced-fit changes in the structures of both proteins. Our study includes the first structure of the complex between MDMX and a small molecule and should aid in developing efficient scaffolds for binding to MDMX and/or MDM2.

[1]  A. Levine,et al.  Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.

[2]  T. Holak,et al.  Molecular Basis for the Inhibition of p53 by Mdmx , 2007, Cell cycle.

[3]  D. Lane,et al.  New developments in small molecules targeting p53 pathways in anticancer therapy , 2008 .

[4]  Alexei Vazquez,et al.  The genetics of the p53 pathway, apoptosis and cancer therapy , 2008, Nature Reviews Drug Discovery.

[5]  A. Fersht,et al.  Structural biology of the tumor suppressor p53. , 2008, Annual review of biochemistry.

[6]  A. Dömling,et al.  Discovery of pyrroloimidazoles as agents stimulating neurite outgrowth , 2006 .

[7]  S. Malek,et al.  The pre-clinical development of MDM2 inhibitors in chronic lymphocytic leukemia uncovers a central role for p53 status in sensitivity to Mdm2 inhibitor-mediated apoptosis , 2008, Cell cycle.

[8]  T. Jacks,et al.  Restoration of p53 function leads to tumour regression in vivo , 2007, Nature.

[9]  L. Vassilev,et al.  MDM2 inhibitors for cancer therapy. , 2007, Trends in molecular medicine.

[10]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[11]  Michael A. Dyer,et al.  Inactivation of the p53 pathway in retinoblastoma , 2006, Nature.

[12]  G. Wahl,et al.  Regulating the p53 pathway: in vitro hypotheses, in vivo veritas , 2006, Nature Reviews Cancer.

[13]  J. Marx.  Recruiting the Cell's Own Guardian for Cancer Therapy , 2007, Science.

[14]  Shaomeng Wang,et al.  Targeting the MDM2-p53 Interaction for Cancer Therapy , 2008, Clinical Cancer Research.

[15]  Neal J. Zondlo,et al.  Determinants of specificity of MDM2 for the activation domains of p53 and p65: proline27 disrupts the MDM2-binding motif of p53. , 2006, Biochemistry.

[16]  Shaomeng Wang,et al.  Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. , 2009, Annual review of pharmacology and toxicology.

[17]  Maxwell D Cummings,et al.  Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. , 2005, Journal of medicinal chemistry.

[18]  Stephen N. Jones,et al.  Regulation of p53 stability by Mdm2 , 1997, Nature.

[19]  Alexander Dömling,et al.  Small molecular weight protein-protein interaction antagonists: an insurmountable challenge? , 2008, Current opinion in chemical biology.

[20]  Chong Li,et al.  Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX , 2009, Proceedings of the National Academy of Sciences.

[21]  Carlos Cordon-Cardo,et al.  Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas , 2007, Nature.

[22]  Baoli Hu,et al.  Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX. , 2007, Cancer research.

[23]  Karen H. Vousden,et al.  p53 in health and disease , 2007, Nature Reviews Molecular Cell Biology.

[24]  Dajun Yang,et al.  Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition , 2008, Proceedings of the National Academy of Sciences.

[25]  G. Dubin,et al.  High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx , 2009, Cell cycle.

[26]  Gerard I. Evan,et al.  Modeling the Therapeutic Efficacy of p53 Restoration in Tumors , 2006, Cell.

[27]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[28]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[29]  T. Holak,et al.  Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain , 2008, Cell cycle.

[30]  S. Gellman,et al.  Targeting protein-protein interactions: lessons from p53/MDM2. , 2007, Biopolymers.

[31]  W. El-Deiry,et al.  Structural and Functional Basis for Therapeutic Modulation of p53 Signaling , 2008, Clinical Cancer Research.

[32]  Mengjia Tang,et al.  Hdmx Modulates the Outcome of P53 Activation in Human Tumor Cells* , 2006, Journal of Biological Chemistry.

[33]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[34]  D. Parks,et al.  Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo , 2006, Molecular Cancer Therapeutics.

[35]  Erik Meulmeester,et al.  p53: a guide to apoptosis. , 2008, Current cancer drug targets.

[36]  M. Geiser,et al.  Crystal Structures of Human MdmX (HdmX) in Complex with p53 Peptide Analogues Reveal Surprising Conformational Changes* , 2009, Journal of Biological Chemistry.

[37]  G. Wahl,et al.  Targeting Mdm2 and Mdmx in Cancer Therapy: Better Living through Medicinal Chemistry? , 2009, Molecular Cancer Research.

[38]  Michael A. Dyer,et al.  MDMX: from bench to bedside , 2007, Journal of Cell Science.

[39]  L. Mayo,et al.  Therapeutic considerations for Mdm2: not just a one trick pony , 2008, Expert opinion on drug discovery.